22. August 2016.
Regional pharmaceutical leader, Hemofarm AD, has acquired the assets of the company ‘Ivancic i sinovi’. This move was initiated, inter alia, by the wish to additionally help the healthcare system of Serbia through the improvement of the market supply with high-quality and available medicines. The company Hemofarm took over the products, the manufacturing plant in Stari Banovci, employees and intellectual property of the company ‘Ivancic’. On behalf of Hemofarm, the sale and purchase agreement was signed by Ronald Seeliger, the CEO of this company.
End-users and the market represent the imperative for Hemofarm. Therefore the company priority is that the effects of this acquisition should be the growth and development of local production, in line with the most demanding global pharmaceutical standards. As a responsible company which also recognizes the public interest in its operations, Hemofarm has undertaken, in cooperation with the partners from the company ‘Ivancic i sinovi’, all the necessary actions to maintain the supply of pharmacies and availability of products and medicines at the highest level. More than thirty products of ‘Ivancic i sinovi’, which have enjoyed the trust of numerous users for years, will remain on the market under the same names in the future as well. In line with its leadership position in the Serbian and regional market, Hemofarm will make these products even more available.
Ronald Seeliger, the CEO of Hemofarm, emphasizes the fact that his company will round up the rich range of OTC products with the acquired portfolio.
‘Hemofarm has been the pharmaceutical leader in the region for years. This event is a piece of a mosaic which fits fantastically in our business strategy. By taking over the products, the plant and the assets of ‘Ivancic i sinovi’, Hemofarm is in a way competing against itself, breaking its own records. In my opinion, that is the hardest, but at the same time, the most challenging thing in business. The skill of assessing the momentum for something new is bordering with ’art’ in the long-term planning, which is a very important segment of production of medicines. This is our moment’, said Seeliger.
Emphasizing the role of employees as the most important resource of the company, Ronald Seeliger also said that he was very happy that the employees of the company ‘Ivancic i sinovi’ would bring new energy to Hemofarm.
‘In a word, I see this acquisition as the benefit for the employees in both companies, and also for the Serbian economy, and especially for the consumers of products’, Ronald Seeliger concluded.
By entering into this agreement, Hemofarm, as the member of the German STADA Group, takes a significant step forward in the further development and progress, following the global pharmaceutical trends.
